Relationship between changes in platelet reactivity and ischemicevents following percutaneous coronary intervention: Ameta-regression analysis of 30 randomized trials

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 176-184

  Piccolo, Raffaele ^a   Galasso, Gennaro ^a   De Luca, Giuseppe ^b   Parodi, Guido ^c   Antoniucci, David ^c   Esposito, Giovanni ^a   Trimarco, Bruno ^a   Piscione, Federico ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antiplatelet therapy; Meta regression; P2Y12 inhibitors; Percutaneous coronary intervention; Platelet reactivity

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; FOLLOW UP; HEART DISEASE; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT RESPONSE; BLOOD; MYOCARDIAL ISCHEMIA; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RISK FACTOR; THROMBOCYTE;

BLOOD PLATELETS; HUMANS; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84897998901     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.024     Document Type: Article

References (61)

1. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA J Am Med Assoc 2011, 306:1215-1223.
2. Aradi D., Komocsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010, 160:543-551.
3. Sibbing D., Byrne R.A., Bernlochner I., Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011, 106:191-202.
4. Stone G.W., Witzenbichler B., Weisz G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013, 382:614-623.
5. Cattaneo M. Diagnosis and management of high platelet reactivity on treatment with clopidogrel. Semin Thromb Hemost 2012, 38:645-651.
6. Collet J.P., Cuisset T., Range G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEngl J Med 2012, 367:2100-2109.
7. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JAm Coll Cardiol 2010, 56:919-933.
8. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JAm Coll Cardiol 2011, 58:e44-122.
9. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W264.
10. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928. Cochrane Bias Methods, G, Cochrane Statistical Methods, GCochrane Statistical Methods, G.
11. Juni P., Witschi A., Bloch R., Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA J Am Med Assoc 1999, 282:1054-1060.
12. Piccolo R., Cassese S., Galasso G., De Rosa R., D'Anna C., Piscione F. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Atherosclerosis 2011, 217:149-157.
13. Hu E.A., Pan A., Malik V., Sun Q. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. BMJ 2012, 344:e1454.
14. Marrone C., Galasso G., Piccolo R., et al. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol 2011, 32:32-39.
15. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
16. Harbord R.M., Egger M., Sterne J.A. Amodified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25:3443-3457.
17. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA J Am Med Assoc 2006, 295:676-680.
18. Aleil B., Jacquemin L., De Poli F., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008, 1:631-638.
19. Alexopoulos D., Dimitropoulos G., Davlouros P., et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011, 4:403-410.
20. Alexopoulos D., Galati A., Xanthopoulou I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. JAm Coll Cardiol 2012, 60:193-199.
21. Alexopoulos D., Theodoropoulos K.C., Stavrou E.F., et al. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther/Sponsored by Int Soc Cardiovasc Pharmacother 2012, 26:393-400.
22. Ari H., Ozkan H., Karacinar A., Ari S., Koca V., Bozat T. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2012, 157:374-380.
23. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. JAm Coll Cardiol 2008, 51:1404-1411.
24. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
25. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. JAm Coll Cardiol 2006, 48:1339-1345.
26. Hobson A.R., Qureshi Z., Banks P., Curzen N. The potential value of near patient platelet function testing in PCI: randomised comparison of 600 mg versus 900 mg Clopidogrel loading doses. Thrombosis 2010, 2010:908272.
27. Jeong Y.H., Lee S.W., Choi B.R., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study. JAm Coll Cardiol 2009, 53:1101-1109.
28. Jeong Y.H., Hwang J.Y., Kim I.S., et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010, 3:17-26.
29. Jeong Y.H., Tantry U.S., Park Y., et al. Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. Diabetes Care 2012, 35:2194-2197.
30. Kim J.Y., Lee K., Shin M., et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J Off J Jpn Circ Soc 2007, 71:1867-1872.
31. Kim I.S., Jeong Y.H., Park Y., et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011, 4:381-391.
32. Kim B.K., Oh S.J., Yoon S.J., Jeon D.W., Ko Y.G., Yang J.Y. Arandomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. Yonsei Med J 2011, 52:717-726.
33. L'Allier P.L., Ducrocq G., Pranno N., et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. JAm Coll Cardiol 2008, 51:1066-1072.
34. Montalescot G., Sideris G., Meuleman C., et al. Arandomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. JAm Coll Cardiol 2006, 48:931-938.
35. Palmerini T., Barozzi C., Tomasi L., et al. Arandomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010, 125:309-314.
36. Patti G., Grieco D., Dicuonzo G., Pasceri V., Nusca A., Di Sciascio G. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. JAm Coll Cardiol 2011, 57:771-778.
37. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA J Am Med Assoc 2011, 305:1097-1105.
38. Roberts J.D., Wells G.A., Le May M.R., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
39. Sardella G., Calcagno S., Mancone M., et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: The RESET GENE Trial. Circ Cardiovasc Interv 2012, 5:698-704.
40. Suh J.W., Lee S.P., Park K.W., et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. JAm Coll Cardiol 2011, 57:280-289.
41. Tousek P., Osmancik P., Paulu P., Kocka V., Widimsky P. Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: a single-center pilot randomised study. Int J Cardiol 2011, 150:231-232.
42. Trenk D., Stone G.W., Gawaz M., et al. Arandomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study. JAm Coll Cardiol 2012, 59:2159-2164.
43. von Beckerath N., Kastrati A., Wieczorek A., et al. Adouble-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007, 28:1814-1819.
44. Wang X.D., Zhang D.F., Zhuang S.W., Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011, 34:332-338.
45. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-2932.
46. Xanthopoulou I., Plakomyti T.E., Theodoropoulos K.F., et al. Low prasugrel vs high clopidogrel dose in patients aged greater than or equal to 75 years with ACS and high on clopidogrel platelet reactivity post PCI. Eur Heart J 2012, 33:317-318.
47. Xanthopoulou I., Theodoropoulos K.F., Kassimis G., et al. Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2012, 33. 41-41.
48. Brar S.S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. JAm Coll Cardiol 2011, 58:1945-1954.
49. Siller-Matula J.M., Francesconi M., Dechant C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013, 167:2018-2023.
50. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009, 119:3215-3222.
51. Collet J.P., Cuisset T., Range G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEngl J Med 2012, 367:2100-2109. Investigators, A.
52. Ahn S.G., Lee S.H., Yoon J.H., et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012, 5:259-267.
53. Reny J.L., Berdague P., Poncet A., et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012, 125:3201-3210. Ischemic Events Study, G.
54. Ritchie M.E. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998, 98:1707-1713.
55. Gresele P., Falcinelli E., Loffredo F., et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J 2011, 32:316-325.
56. Sibbing D., von Beckerath O., Schomig A., Kastrati A., von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis Int J Haemost Thromb 2007, 18:335-339.
57. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2007, 357:2001-2015.
58. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2009, 361:1045-1057.
59. Roe M.T., Armstrong P.W., Fox K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. NEngl J Med 2012, 367:1297-1309.
60. Lassere M.N. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008, 17:303-340.
61. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA J Am Med Assoc 2010, 303:754-762.